Verastem Exercises Option Early to License Cancer Drug VS-7375 From GenFleet

MT Newswires Live01-14

Verastem (VSTM) exercised an option early to license from GenFleet Therapeutics the investigational drug VS-7375, which is in phase 1 development in China for potential treatment of advanced solid tumors in pancreatic, colorectal and non-small cell lung cances.

A US investigational new drug application for VS-7375 is expected to be filed in Q1 with plans to start a phase 1/2a study in the middle of this year, Verastem said Tuesday in a statement.

The license gives Verastem global development and commercialization rights for VS-7375 outside of the GenFleet markets of mainland China, Hong Kong, Macau and Taiwan.

Preliminary results from a phase 1 study of VS-7375 conducted by GenFleet in China showed "partial responses, including patients with pancreatic and lung cancers," Verastem said.

GenFleet had announced 26 people were treated with VS-7375 in the phase 1 dose-escalation trial, Verastem said.

Verastem shares rose 4.1% in recent Tuesday trading.

Price: 5.56, Change: +0.22, Percent Change: +4.11

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment